Piomic, our Swiss Diabetes Venture Fund portfolio company, enrolls first patients in MAVERICKS U.S. study after Medicare Category B designation. FDA-approved IDE study sets groundwork for device authorization and commercialization.
Piomic, our Swiss Diabetes Venture Fund portfolio company, enrolls first patients in MAVERICKS U.S. study after Medicare Category B designation. FDA-approved IDE study sets groundwork for device authorization and commercialization.
